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Development of a soft-tissue sarcoma is an infre-
quent but well-known long-term complication of
radiotherapy. Malignant fibrous histiocytomas, ex-
traskeletal osteosarcomas, fibrosarcomas, malig-
nant peripheral nerve sheath tumors, and angiosar-
comas are most frequently encountered. Radiation-
associated synovial sarcomas are exceptional. We
report the clinicopathologic, immunohistochemi-
cal, and molecular features of two radiation-
associated synovial sarcomas. One tumor developed
in a 42-year-old female 17 years after external irra-
diation was given for breast carcinoma; the other
occurred in a 34-year-old female who was irradiated
at the age of 7 years for a nonneoplastic condition of
the left hand. Both lesions showed morphologic fea-
tures of monophasic spindle cell synovial sarcoma,
were immunoreactive for cytokeratins, epithelial
membrane antigen, CD99, CD117 (c-kit), and bcl-2
and bore the t(X;18) (SYT-SSX1) translocation. We
conclude that synovial sarcoma has to be added to
the list of radiation-associated soft-tissue sarcomas.
KEY WORDS: Cytogenetics, Molecular biology, Pa-
thology, Radiation-associated sarcoma, Radiation
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Accounting for 10 to 15% of soft tissue sarcomas,
synovial sarcoma (SS) is a relatively rare neoplasm
that occurs predominantly in adolescents or young
adults and presents as a large, deep-seated, limb-
based mass, often in close association with large
joints (knees and hips; 1, 2). Occasionally, it devel-
ops in older patients and/or involves unusual sites
such as the abdominal wall, the head and neck
region, or viscera (1, 2). SS bears the t(X;18) (SYT-
SSX) reciprocal translocation that seems to be spe-
cific for this tumor type and can be routinely de-
tected in paraffin-embedded tissue using the
reverse transcriptase–polymerase chain reaction
(RT-PCR; 3– 6). Radiation-associated sarcomas are
an infrequent but well-known long-term complica-
tion of radiotherapy (7–16). They occur in about
1/1000 patients who have undergone radiation
therapy (7–11). Radiation-associated sarcomas are
defined as sarcomas arising in a previously irradi-
ated field after a latency period of 2 years (12).
They usually show a more aggressive clinical course
associated with shortened patient survival as com-
pared with sporadic sarcomas (9 –12, 14). High-
grade pleomorphic sarcomas including so-called
malignant fibrous histiocytomas, extraskeletal os-
teosarcomas, and fibrosarcomas are the histologi-
cal types most frequently encountered; extraskel-
etal chondrosarcomas, malignant schwannomas,
leiomyosarcomas, and angiosarcomas are much
rarer (7, 9 –12, 14 –16). Postradiation SS is excep-
tional. To our knowledge, only two cases have been
previously described (17, 18), of which one only was
fully documented and bore the t(X;18) (SYT-SSX)
translocation (18). In the present study, we describe
two additional cases of radiation-associated SS.
They occurred in previous radiation fields after la-
tent periods of 17 and 27 years and showed classical
histologic, immunohistochemical, and molecular
features of SS.
CASE REPORTS
Case 1
A 25-year-old white woman presented in 1981
with a painless 4.5-cm mass located in the su-
praareolar region of the right breast. There were no
palpable axillary lymph nodes. A right mastectomy
with lympadenectomy was performed in June 1981,
and a pathologic diagnosis of poorly differentiated
(Grade 3) invasive ductal carcinoma of the breast
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with concomitant axillary lymph node metastases
was rendered. Subsequently, she received a total
dose of 50 Gy to her right breast area, a 21-Gy boost
to the tumor area, 52 Gy to the supraclavicular and
axillary lymph nodes, and 48 Gy to the parasternal
node fields. This radiotherapy regimen was given
over a 2-month period without any major side ef-
fects; the number of sessions was not known. Com-
plete remission was obtained and the patient dis-
charged. After a 17-year disease-free latency period,
she complained of an infraclavicular mass that ap-
peared in the previous irradiated region. The mass
measured 5.5 cm in maximal diameter and was
situated within minor pectoral muscle, deep to the
clavipectoral fascia. It extended to the previously
cleared right axilla. This mass was marginally ex-
cised. The patient did not received any radiother-
apy or chemotherapy after surgery. Nineteen
months later, the tumor recurred locally and was, at
that time, widely excised. Three months later, there
was no evidence of local recurrence or distant
metastasis.
Case 2
A 34-year-old woman presented with a 2-cm
painless mass situated between the second and
third metacarpus of the left hand. The nodule grad-
ually enlarged for 7 months before she sought med-
ical attention. At the age of 7 years, she had been
irradiated for a congenital hemihypertrophy of the
left distal extremity and left-hand gigantism caused
by an angiomatous malformation. Doses and frac-
tions were not known. The mass of the left hand
was surgically removed and proved to be, on mi-
croscopic examination, a 6-cm, Grade 3 monopha-
sic SS. Surgical margins were positive for tumor.
Because of the presence of a visible residual tumor
on postoperative magnetic resonance images, a
postoperative chemotherapy was given, consisting
of six courses of a combination of dacarbazine,
ifosfamide, and doxorubicin followed by an ampu-
tation of the third metacarpus and finger. Patholog-
ical examination confirmed the presence of resid-
ual SS. The patient refused hand amputation and
thus was given a total dose of 50.4 Gy in 28 sessions
to the left hand. Twelve months later, left pleural
effusion developed. Chest radiograms and com-
puted tomography films revealed pulmonary me-
tastases, including a 2-cm nodular mass in the
lower lobe of the left lung. The patient currently is
being treated with systemic chemotherapy for her
metastatic disease.
MATERIALS AND METHODS
Tissue for light-microscopic examination was
fixed in 4% phosphate-buffered formalin and em-
bedded in paraffin. Four-m-thick sections were
stained with hematoxylin and eosin. The mitotic
count was performed using a 40 lens (high-power
field: 0.174 mm2). Histologic typing and subtyping
were performed on paraffin-embedded sections
stained with hematoxylin and eosin, using the
World Health Organization histological classifica-
tion of soft tissue tumors (19). Additional sections
were stained with the following monoclonal and
polyclonal antibodies: cytokeratin (monoclonal,
clone AE1/AE3, diluted 1/100; Novocastra Labora-
tories Inc., Dedham, MA), epithelial membrane an-
tigen (monoclonal, clone E29, diluted 1/50; Dako-
patts, Glostrup, Denmark), CD34 (monoclonal,
clone Qbend 10, diluted 1/80, Immunotech, Mar-
seille, France), smooth muscle actin (monoclonal,
clone 1A4, diluted 1/500, Sigma Chemical Com-
pany, St. Louis, MO), desmin (monoclonal, clone
D33, diluted 1/40, Dakopatts), S100 protein (poly-
clonal rabbit, prediluted/ChemMate, DAKO), CD99
(monoclonal, clone 013, diluted 1/20, Signet Labo-
ratories Inc., Dedham, MA), bcl-2 (monoclonal,
clone bcl-2/100/D5, diluted 1/50, Novocastra Lab-
oratories, Ltd, Newcastle upon Tyne, UK), and
CD117 (c-kit; polyclonal rabbit, diluted 1/50,
DAKO). Immunostaining was performed according
to the avidin biotin complex method of Hsu et al.
(20) with overnight incubation for bcl-2 antibody.
Tissue sections were submitted to microwave oven
heating before staining. All steps were performed at
room temperature, and diaminobenzidine was
used as a chromogen. Appropriate positive and
negative controls were employed throughout.
RNA Extraction
Approximately 50 mg of tumor were removed
from paraffin blocks by scraping with a sterile scal-
pel. The tissue samples were deparaffinized by in-
cubation 5 minutes in 1 mL of xylene at 65° C; this
reaction was repeated to remove residual paraffin.
After centrifugation, the tissue was washed with 1
mL of 100% ethanol, followed by 1 mL of 70%
ethanol. After 5 minutes of vacuum drying, the pel-
let was suspended in 250 L of lysis buffer (20
mmol/L of Tris-HCl, pH 7.5; 20 mmol/L of EDTA;
1% sodium dodecyl sulfate; and 350 –500 g of pro-
teinase K). The lysis buffer was preincubated at 37°
C for 30 minutes before tissue addition. After 16 to
48 hours’ incubation at 55° C, 750 L of Trizol-LS
reagent (Gibco BRL, Gaithersburg, MD) was added
to the sample, and total RNA was extracted accord-
ing to the manufacturer’s instructions. The RNA
pellet was redissolved in 40 L of RNase-free water
and stored at 80° C. The quantity of the isolated
RNA was determined by absorbance at 260 and 280
nm.
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RT-PCR Analysis
Approximately 5 g of the extracted RNA was
reverse transcribed into complementary DNA
(cDNA), at 42° C for 50 minutes, in a volume of 20
L with the specific reverse primers (65 ng of SSX-B
and 15 ng of -actin-B), 0.5 mmol/L of dNTP, 10
mmol/L of dithiothreitol, 50 mmol/L of Tris-HCl
(pH 8.3), 40 mmol/L of KCl, 5 mmol/L of MgCl2, 10
U of RNase inhibitor, and 10 U of Expand Reverse
Transcriptase (Roche Diagnostics, Germany). The
reverse transcriptase was inactivated at 98° C for 5
minutes, and the solution was kept at 20° C until
use. The amplification reactions (20 L) were per-
formed, in presence of 2 L of the cDNA reaction,
with an initial incubation step at 95° C for 5 min-
utes. The amplification profile of the PCR consisted
of 35 cycles of denaturation at 94° C for 30 seconds,
annealing at 60° C for 45 seconds, and extension at
72° C for 75 seconds. For each sample, two PCR
amplifications were performed in parallel. One con-
tained only the primer set necessary for the ampli-
fication of the SYT-SSX fusion gene transcripts,
whereas the other was spiked with a set of primers
for the ubiquitously expressed -actin gene tran-
scripts. -actin primers were used at a lower con-
centration than were SYT-SSX fusion gene tran-
script primers (1 pmol in 20-L PCR reaction,
instead of 10 pmoles for SYT-SSX). PCR amplifica-
tions were performed with the following primers:
SYT-A (5'-CAGCAGAGGCCTTATGGATATGA-3'),
SSX-B (5'-TTTGTGGGCCAGATG), -actin-A (5'-
AGGCCAACCGCGAGAAGATGA-3'), and -actin-B
(5'- GCCGTGGTGGTGAAGCTGTAG-3'). The reac-
tion products were subjected to electrophoresis in
2% agarose gel and visualized by ethidium bromide
staining. The size of PCR products was 97 bp for the
SYT-SSX (SYT-SSX1 or SYT-SSX2) fusion gene tran-
scripts and 274 bp for the -actin messenger RNA.
The RT-PCR procedure was performed at least
twice for each sample. For each PCR procedure, a
classic t(X;18)-positive biphasic SS was used as a
positive control. Negative controls consisted of t(X;
18)-negative desmoid tumor, 5  105 (5 L) SW480
colorectal cancer cells, as well as distilled water
devoid of template cDNA.
Subtyping of the SYT-SSX Fusion Transcripts
Three microliters of each PCR product was enzy-
matically hydrolyzed at 65° C for 1 hour with 5 units
of the restriction enzyme TaqI (Roche) in a final
volume of 10 L. The digestion patterns of the PCR
products were analyzed on 2% agarose gels and
visualized by ethidium bromide staining. The size
of digested products were 65 and 32 bp for the
SYT-SSX1 fusion gene transcripts but remained at
97 bp for SYT-SSX2.
Subtyping was determined in parallel by single-
strand conformation polymorphism analysis. Ali-
quots of 5 L of PCR products were mixed with 5 L
of denaturing buffer (0.1 M NaOH and 2 mM EDTA),
heated at 50° C for 10 minutes. After addition of 1
L of formamide dye, the samples were immedi-
ately loaded onto a 40% MDE gel (FMC BioProd-
ucts, Rockland, ME) and electrophoresed in 0.5
TBE buffer at 20° C and 300V (20V/cm) for 5 hours.
The gels were stained with a SYBR Gold gel stain
(Molecular Probes, Eugene, OR) diluted 1:10,000 in
1 TBE buffer and visualized under ultraviolet light
using a CCD camera.
RESULTS
The two tumors show similar morphological, im-
munohistochemical, and molecular features. On
microscopic examination, both neoplasms showed
features of monophasic SS. They corresponded to
highly cellular proliferations of spindle to round
cells with relatively uniform fibroblast-like nuclei,
arranged in fascicles or whorls, set in a variably
collagenized intercellular matrix (Figs. 1 and 2).
Numerous interspersed mastocytes and areas of
myxoid changes were also present. In addition, dys-
trophic calcifications were visible in Case 1 (Fig. 1),
and minute foci of tumor necrosis, in Case 2. The
mitotic activity ranged from 4 (Case 1, primary tu-
mor) to 16 (Case 2) mitoses per 10 high-power
fields. The tumor recurrence in Patient 1 was
slightly more cellular (or less myxoid) and more
mitotically active (14 mitoses per 10 high-power
fields) as compared with the case of the primary.
Immunohistochemically, tumor cells in both
neoplasms were positive, at least focally, for EMA
(Fig. 3A), bcl-2, CD99, and CD117 (c-kit). Both le-
sions also contained scattered isolated cells and/or
FIGURE 1. Case 1. Fascicular spindle cell proliferation with scattered
minute dystrophic calcifications. Hematoxylin and eosin stain, 20.
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small tumor cell aggregates that were positive for
cytokeratin (Fig. 3B), whereas stainings for S100
protein, HMB-45, desmin, and CD34 were negative.
Few cells were also positive for smooth muscle ac-
tin in Case 2.
The two neoplasms bore the translocation t(X;
18)(SYT-SSX) (Fig. 4); the SSX1 gene was involved in
both cases, including in the local recurrence of
Patient 1 (data not shown).
DISCUSSION
SS is a relatively rare, deep-seated, often highly
aggressive and metastasizing neoplasm that occurs
frequently but not exclusively in adolescents and
young adults. It involves primarily the limbs, espe-
cially lower limbs, where it is usually found in close
association with large joints, but it can also be
observed in less common locations including ab-
dominal wall, chest, mediastinum, bone, and vis-
cera such as tonsil, pharynx, larynx, lungs, pleura,
prostate, and so on (1, 2). This combination of rarity
and unexpected situation is often a source of diag-
nostic difficulties for pathologists. The diagnostic
issue is compounded by the fact that several histo-
logic variants of SS have been described, including
the biphasic, monophasic spindle-cell, poorly
differentiated/round-cell, myxoid, calcifying, and
bone-forming forms (1, 2). Immunohistochemistry
and electron microscopy are very helpful ancillary
techniques in this context. SS cells usually stain for
epithelial membrane antigen, cytokeratins (few
cells only), bcl-2, and CD99 but not for CD34 (1, 2).
Approximately 30% of SS are positive for S100 pro-
tein (21), and this has to be taken into consider-
ation in the differential diagnosis with malignant
schwannoma. Ultrastructurally, the spindle cells
show inconstant features of epithelial differentia-
tion (rudimentary intercellular junctions, external
lamina; 1, 2).
The recent demonstration that SS bears a specific
chromosomal translocation t(X,18)(SYT-SSX) has
provided an additional tool for diagnosing equivocal
cases and those displaying minimal or no immuno/
ultrastructural expression of epithelial differentiation
(3–6). The translocation t(X;18) that involves mainly
the SSX1 or SSX2 genes, two closely related genes
from chromosome Xp11, and the SYT gene from
chromosome 18q11 result in the formation of a chi-
meric gene that encodes a transcription-activating
protein. Using a consensus primer for SSX1 and
SSX2, fusion gene transcripts may be detected in
frozen tissue samples (5, 6, 22) and in formalin-
fixed, paraffin-embedded material (3, 4, 6), using
the reverse transcriptase–polymerase chain reaction
(RT-PCR), regardless of the treatment (chemotherapy
or radiation therapy) given to the patient before mo-
lecular analysis (6)
FIGURE 2. Case 2. Proliferation of round to spindle cells with opened
chromatin nuclei and vague fascicular arrangement. Hematoxylin and
eosin stain, 40.
FIGURE 3. Case 2. Focal positivity of the spindle cells for epithelial
membrane antigen (A) and cytokeratin (B).
FIGURE 4. Detection of the t(X;18) (SYT-SSX) translocation in two
radiation-associated synovial sarcomas using RT-PCR. Lanes 1 and 2
correspond to Cases 1 and 2, respectively. For Lane 1, PCR
amplifications contained only the primer set necessary for the
amplification of SYT-SSX fusion gene transcripts, whereas in Lanes 2, 3,
and 4 they were spiked with a set of primers for the ubiquitously
expressed -actin gene transcripts (positive control). A biphasic
synovial sarcoma (Lane 3) was used as a positive control for the t(X;
18) detection. Negative controls consisted of t(X;18)-negative desmoid
tumor (Lane 4) as well as distilled water devoid of template cDNA
(Lane 5). Lane 6, pGEM DNA size markers (Promega, Madison, WI).
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Ionizing radiation is currently recognized as a
predisposing factor for cancer development in pa-
tients treated for both malignant and nonmalignant
conditions. Among those radiation-related tumors,
carcinomas, bone tumors, and leukemias are most
frequently encountered (12). Criteria currently in
use for defining postradiation neoplasms are as
follows: (1) prior history of irradiation; (2) develop-
ment of a secondary neoplasm in the field previ-
ously irradiated; (3) a latency period of 2 years
between radiation and the emergence of the second
tumor; (4) proof that the secondary tumor is histo-
logically different from the irradiated primary tu-
mor (11, 12). Our two cases fulfilled those criteria
and thus can be considered as radiation-associated
SSs. Latency periods (17 and 27 y) are in keeping
with the time interval of 2 to 64 years (mean: 10 to
17 y) reported for postradiation non-SSs (7, 9 –12,
14 –16). Along the same line, the amount of radia-
tion received (71 Gy for one of our cases) is also in
keeping with literature data (7, 9 –12, 15, 16).
Malignant fibrous histiocytomas, extraskeletal
osteosarcomas, fibrosarcomas, malignant periph-
eral nerve sheath tumors (malignant schwanno-
mas), and angiosarcomas are the most frequently
encountered postradiation sarcomas (10 –12, 14 –
16). Radiation-associated SSs seem to be exceed-
ingly rare, with only two cases reported heretofore
(17, 18), the clinicopathologic features of which are
summarized in Table 1. Only one case (18) that
includes immunohistochemical data and shows the
presence of the t(X;18) SS translocation is ade-
quately documented. The case reported by Mis-
chler et al. (17) that is poorly illustrated and lacks
immunohistochemical and molecular analysis re-
mains questionable. On the single illustration pro-
vided, the morphology of the neoplasm is in keep-
ing with a biphasic SS but could fit with a glandular
malignant schwannoma, a carcinosarcoma, or a
mesothelioma as well.
On the basis of three acceptable cases of pos-
tradiation SS (18; present cases), it appears that
postradiation sarcomas do not differ clinically,
morphologically, immunohistochemically, and
molecularly from sporadic SS. All three cases
were monophasic spindle to round-cell SS, and as
expected, all variably express EMA, cytokeratins,
bcl-2, and CD99 and were consistently negative
for CD34. Reactivity for CD117 was focally ob-
served in our two cases. As experience accumu-
lates, it appears that some mesenchymal tumors
other than gastrointestinal stromal tumors may
express CD117 including angiosarcomas, Ewing’s
sarcoma/PNET (23, 24), and SSs (25). The SSX1
gene was involved in our two postradiation SS,
contrasting with the SYT-SSX2 translocation ob-
served in the case of van de Rijn et al. (18). In
sporadic monophasic spindle- to round-cell SS, TA
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the t(X;18) (SYT-SSX) translocation may involve
either the SSX1 or the SSX2 genes (6, 22). We
recently examined a series of 100 monophasic SS
and found that the SSX1 gene was involved in
60% of the cases (unpublished data), a gene ratio
that seems to be observed also in postradiation
monophasic SS. Molecular studies on SS showed
that the fusion gene type (SYT-SSX1 versus SYT-
SSX2) is concordant in primaries, recurrences,
and metastases and is also constant over the
course of the disease regardless of the treatment
(radiotherapy and/or chemotherapy) given (6,
22). This also applies to postradiation SS because
the same SYT-SSX1 translocation was observed in
the primary tumor and the subsequent recur-
rence of one of our cases.
Differential diagnoses of radiation-associated SS
mainly included recurring spindle-cell (sarcoma-
toid) carcinoma, monophasic spindle cell mesothe-
lioma, fibrosarcoma, and malignant peripheral
nerve sheath tumor (MPNST). Cellular schwan-
noma, malignant hemangiopericytoma, Ewing’s
sarcoma/PNET, melanoma, malignant extrapleural
solitary fibrous tumor, and other spindle- to round-
cell nonSSs should also be eliminated (1, 2). In a
context of previously irradiated carcinoma, as in
one of our cases, a postradiation spindle cell tumor
is likely to be first diagnosed as a carcinomatous
recurrence in the form of metaplastic or sarcoma-
toid carcinoma. Immunohistochemistry is not very
helpful in making the distinction with SS because
both tumor types may be positive, at least focally,
for epithelial markers. Spindle cell carcinoma, how-
ever, is generally more pleomorphic and heteroge-
neous than SS and, more important, lacks the t(X;
18) translocation. There is a great morphological
overlap between fibrosarcoma, MPNST, and SS,
and many monophasic spindle cell SS were labeled
as fibrosarcomas in the past. Thus, it is conceivable
that some of those postradiation fibrosarcomas re-
ported several years ago (11–13) might actually cor-
respond to true monophasic spindle cell SS. Tumor
cells in fibrosarcomas usually show a characteristic
fascicular herringbone arrangement and are nega-
tive for keratins and EMA, as opposed to most SS. In
MPNST, alternating hypercellular and myxoid areas
are commonly observed in addition to a tendency
for the tumor cells to form perivascular whorls and
to infiltrate blood vessel walls, features which are
less frequent in SS. Tumor cells in MPNST are also
rarely positive for epithelial markers and almost
never positive for cytokeratins 7 and 19, keratin
subsets that are consistently found in SS (26). In
addition, neither fibrosarcoma nor MPNST bear the
t(X;18) translocation, despite recent claims (27) that
are likely to be ill founded (28).
As stressed by van de Rijn et al. (18), one may
argue that the association between previous irradi-
ation and SS occurrence is purely fortuitous. We
recently reviewed the clinicopathologic features
and outcome of 130 t(X;18)-positive SS and found
only two (1.5%) cases (present cases) that had oc-
curred in previous irradiation fields. Although we
have no proof for that, it seems reasonable to think
that ionizing radiation has played a significant role
in the development of these secondary neoplasms,
but other causes (unrecognized carcinogenes, ge-
netic predisposition, and so on), taken in isolation
or in combination might also have been oncogenic.
Of interest was that none of our patients received
chemotherapy in addition to radiation therapy for
the original neoplasm.
In conclusion, this report shows that SS may de-
velop in previous radiation treatment fields and,
thus, should be added to the list of radiation-
associated soft tissue sarcomas.
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